British drug maker GlaxoSmithKline has announced that US regulators have approved its swine flu vaccine for adults in the United States.
"The US Food and Drug Administration (FDA) has approved a... license application for its unadjuvanted influenza A (H1N1) pandemic vaccine," GSK said in a statement received on Wednesday.
"The United States Department of Health and Human Services has placed an order to fill 7.6 million doses of unadjuvanted H1N1 pandemic vaccine from GSK, which will contribute to the approximately 250 million doses secured by the US government."
Although the vaccine is used to fight swine flu, its make-up is different to Pandemrix -- GSK's drug recently approved by EU regulators to treat swine flu in Europe.
(c) 2009 AFP
Explore further: Study examines FDA influence on design of pivotal drug studies